EP3057635A1 - Dispositifs de transfert de fluide et leurs systèmes et procédés d'utilisation pour distribuer des fluides médicaux - Google Patents

Dispositifs de transfert de fluide et leurs systèmes et procédés d'utilisation pour distribuer des fluides médicaux

Info

Publication number
EP3057635A1
EP3057635A1 EP14853288.0A EP14853288A EP3057635A1 EP 3057635 A1 EP3057635 A1 EP 3057635A1 EP 14853288 A EP14853288 A EP 14853288A EP 3057635 A1 EP3057635 A1 EP 3057635A1
Authority
EP
European Patent Office
Prior art keywords
outer shell
fluid flow
fluid
flow path
inner housing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14853288.0A
Other languages
German (de)
English (en)
Other versions
EP3057635B1 (fr
EP3057635A4 (fr
Inventor
David K. Stroup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infusion Innovations Inc
Original Assignee
Infusion Innovations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infusion Innovations Inc filed Critical Infusion Innovations Inc
Publication of EP3057635A1 publication Critical patent/EP3057635A1/fr
Publication of EP3057635A4 publication Critical patent/EP3057635A4/fr
Application granted granted Critical
Publication of EP3057635B1 publication Critical patent/EP3057635B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2096—Combination of a vial and a syringe for transferring or mixing their contents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1406—Septums, pierceable membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2006—Piercing means
    • A61J1/201—Piercing means having one piercing end
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/202—Separating means
    • A61J1/2044—Separating means having slits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2048—Connecting means
    • A61J1/2051—Connecting means having tap means, e.g. tap means activated by sliding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2048—Connecting means
    • A61J1/2055—Connecting means having gripping means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2048—Connecting means
    • A61J1/2058—Connecting means having multiple connecting ports
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2079—Filtering means
    • A61J1/2082—Filtering means for gas filtration

Definitions

  • Injection safety refers to the proper use and handling of supplies for administering injections and infusions (e.g., syringes, needles, intravenous tubing, medication vials, and parenteral solutions). These practices are intended to prevent transmission of materials between one patient and another, or between a patient and healthcare personnel during preparation and administration of parenteral medications. Safe injection practices are vitally important in infection control in the medical setting.
  • supplies for administering injections and infusions e.g., syringes, needles, intravenous tubing, medication vials, and parenteral solutions.
  • Parenteral medications are typically packaged in containers such as vials, ampoules, and flexible bags, from which the medication is administered via a transfer device.
  • the transfer device typically comprises a first section which is designed to pierce a septum or other seal on the medication container, thereby permitting access to the contents, and a second section for sealingly and releasably mating with a fluid delivery device such as a syringe or infusion tubing.
  • Assemblies which have hitherto been proposed for the aseptic administration of drugs are described in U.S. Pat. Nos. Des.
  • US2012/0157914 which is hereby incorporated in its entirety, describes an apparatus and method for controlling flow through a fluid line or device for, inter alia, delivering fluid via an intravenous or other medical fluid line into a patient, a syringe, container, and/or other medical device, and systems including such connectors and/or valves.
  • a valve assembly which may be coupled to a container defines a fluid path from the container when the valve assembly is in an open condition, and prevents flow of fluid from the container when the valve assembly is in a closed condition.
  • An inner housing if the valve assembly is movable relative to its outer housing, and a rotational force moves a sealing pin within the inner housing between a first, closed position and a second, open position.
  • This system provides a sequential locking mechanism which cab mechanically prevent accidental discharge of a medication, and provide a visual indicator confirming the status (open or closed) of the connection between the container, transfer device, and fluid delivery device.
  • IV intravenous
  • the invention provides a device for controlling fluid flow, referred to herein as a fluid transfer device, comprising:
  • a sealing member positioned within the first fluid flow path, the sealing member comprising a resilient body and a pressure-actuated opening in the resilient body configured to reversibly control flow through the first fluid flow path, and
  • a pressure member movably engaged within the first outer shell on the distal side of the sealing member such that the pressure member is movable relative to the first outer shell from a first position to a second position, the first position configured to permit the resilient body to close the pressure actuated opening, and the second position configured to permit flow through the first fluid flow path by opening of the pressure- actuated opening.
  • the fluid transfer device may be provided as a standalone element for mating with a corresponding valve actuating device which is configured to control the pressure- actuated opening.
  • the valve actuating device comprises:
  • one or more second engagement structures a surface of the second outer shell at the proximal end thereof, wherein the proximal end of the second outer shell is configured to reversibly mate with the distal end of the first outer shell, and the first and second engagement structures are configured to retain the first outer shell to the second outer shell in a reversibly locked configuration by rotation of the first outer shell relative to the second outer shell,
  • an inner housing movably engaged within the second outer shell such that the inner housing is movable relative to the second outer shell from a first position to a second position by rotational movement of the second outer shell relative to the inner housing, the inner housing comprising a central boss providing a through bore defining at least part of the second fluid flow path,
  • a sealing pin coupled to the second outer shell and extending into the through bore of the central boss, the sealing pin having a first end which is configured for sealing engagement in the central boss through bore to prevent fluid flow through the second fluid flow path in the first position of the inner housing, and which is configured to permit flow through the second fluid flow path by separating from the central boss in the second position of the inner housing, wherein when the first outer shell and the second outer shell are engaged in the reversibly locked configuration, movement of the inner housing from its first position to its second position applies pressure to the pressure member, thereby moving the pressure member from its first position to its second position to fluidly connecting the first and second fluid flow paths.
  • the fluid transfer device and the valve actuating device are provided and/or used together as a system for controlling fluid flow. These may be provided in a single package, or in separate packaging.
  • the packaging is configured to enclose, and to provide a sterile internal environment for, the fluid transfer device and/or the valve actuating device.
  • the distal and/or proximal ends of the fluid transfer device and/or the valve actuating device may be provided with a removable seal in order to inhibit microbial contamination prior to use of the device(s). Such seals are intended to be peeled from the end of the device by the end user at the time of use.
  • the first outer shell comprises a spike member at the proximal end thereof.
  • This spike member may take the form of an IV bag spike or a piercing member for piercing the septum on a medication vial for example.
  • the purpose of this spike member is to fluidly connect the interior of the medical container to the first flow path, so that the fluid transfer device may operate to pass fluid when actuated.
  • the first outer shell may also comprise a filter element fluidly connected to a vent aperture configured to provide pressure equalization between the first fluid flow path and atmospheric pressure. This can facilitate volume removal from the medication container without creating a pressure differential within the container, and can reduce spray of toxic chemicals from inside the medication container during use.
  • the spike member may be configured as a "dual channel" member, with one channel providing fluid transfer, and the other channel providing pressure equalization. Examples of such filters are disclosed in U.S. Patent 7,326,194, which is hereby incorporated by reference in its entirety.
  • movement of the inner housing from its first position to its second position causes a status indicator comprising a colored outer surface portion of the inner housing to extend from the second outer shell, wherein extension of the status indicator indicates fluid connection of the first and second fluid flow paths.
  • the distal end of the second outer shell can comprise a set of connector threads surrounding a boss on one end and a passage through the boss to an outlet end opening.
  • This can take the form of, for example, a male or female luer fitting to facilitate attachment of a corresponding piece of medical equipment such as a syringe, flow line (cannula, catheter, etc.).
  • the connector threads take the form of a female Luer-Lock® (Becton Dickinson) fitting having a hub configured to screw into threads in a sleeve on a luer male fitting.
  • the devices and systems disclosed herein may be used in methods for the control and/or administration of fluids. Such methods comprise: providing a fluid transfer device and a valve actuating device as described herein; fluidly connecting the first fluid flow path to the fluid medication; mating the proximal end of the second outer shell with the distal end of the first outer shell and rotating the first outer shell relative to the second outer shell to engage the first and second engagement structures, thereby retaining the first outer shell to the second outer shell in a reversibly locked configuration; rotating the second outer shell relative to the inner housing such that the inner housing is moved from its first position to its second position, thereby moving the pressure member from its first position to its second position to fluidly connect the first and second fluid flow paths; fluidly connecting the patient fluid delivery device to the second fluid flow path; and inducing flow of the fluid medication from the medication container to the fluid delivery device.
  • these methods may further comprise rotating the second outer shell relative to the inner housing such that the inner housing is moved from its second position to its first position, thereby causing the resilient body to close the pressure actuated opening; and removing the first outer shell from the second outer shell by rotating the first outer shell relative to the second outer shell to disengage the first and second engagement structures.
  • proximal refers to a first end of the device and “distal” refers to a second opposite end of the device.
  • Actuated refers to the condition in which the fluid path is opened to allow fluid to transfer freely along the fluid path
  • deactuated refers to the condition in which the fluid path is closed and fluid transfer is not permitted
  • Engaged or “mated” refers to the condition in which two members that are designed for connection, for example, Luer connectors, are physically connected to each other in a manner in which they are designed to be connected, while “disengaged” refers to the condition in which two members, for example, Luer connectors, are physically disconnected from one another.
  • engaged When two members are referred to as “engaged,” they may or may not be “actuated.” The two members are “actuated” only when they are fully engaged, and fluid transfer is permitted between them.
  • FIG. 1 depicts an exemplary embodiment of a fluid transfer device of the present invention adapted for use with a fluid vial.
  • FIG. 2 depicts an alternate view of the exemplary embodiment of a fluid transfer device of the present invention.
  • FIG. 3 depicts a cross-sectional view of the exemplary embodiment of a fluid transfer device of the present invention.
  • Fig. 4 depicts a cross-sectional view of the exemplary embodiment of a fluid transfer device of the present invention in fluid communication with the interior of a fluid vial.
  • FIG. 5 depicts an exploded view of a fluid transfer device and a corresponding valve actuating device according to the present invention.
  • FIG. 6 depicts a cross-sectional view of the exemplary embodiment of a fluid transfer device and a corresponding valve actuating device of the present invention in fluid communication with the interior of a fluid vial.
  • Fig. 7 depicts an alternative configuration of a fluid transfer device of the present invention adapted for use with an IV bag.
  • Fig. 8 depicts a configuration of a fluid transfer device of the present invention comprising a flexible enclosure which provides an entrapment reservoir such that any aerosol that exits the vial is entrapped within the enclosure.
  • Fig. 9 depicts assembly of a configuration of a fluid transfer device of the present invention comprising a flexible enclosure which provides an entrapment reservoir.
  • Fig. 10 depicts assembly of a configuration of a fluid transfer device of the present invention comprising a flexible enclosure which provides an entrapment reservoir.
  • Fig. 11 depicts assembly of a configuration of a fluid transfer device of the present invention comprising a flexible enclosure which provides an entrapment reservoir.
  • Fig. 12 depicts assembly of a configuration of a fluid transfer device of the present invention comprising a flexible enclosure which provides an entrapment reservoir.
  • Fig. 13 depicts a configuration of a fluid transfer device of the present invention comprising a physical capture device that prevents aerosolization of vial contents such that any aerosol that exits the vial is entrapped within the physical capture device.
  • Fig. 14 depicts an alternate view of the configuration of a fluid transfer device of the present invention comprising a physical capture device that prevents aerosolization of vial contents such that any aerosol that exits the vial is entrapped within the physical capture device.
  • Fig. 15 depicts a configuration of a fluid transfer device of the present invention comprising a physical capture device in the form of a filter that prevents aerosolization of vial contents such that any aerosol that exits the vial is captured by the physical capture device.
  • Fig. 16 depicts an alternate view of the configuration of a fluid transfer device of the present invention comprising a physical capture device in the form of a filter that prevents aerosolization of vial contents such that any aerosol that exits the vial is captured by the physical capture device.
  • Fig. 1 depicts an exemplary embodiment of a fluid transfer device, generally designated 100, constructed and operative in accordance with the teachings of the present invention for enabling control of fluid flow from a medicinal vessel 200.
  • the fluid transfer device 100 includes an elongated outer shell base member 102 which is covered at its distal end by a removable protective cover 101.
  • the fluid transfer device typically include a lumen defining a flow path defined by a proximal end and a distal end connected by a lumen, and a flow control member for controlling flow from the proximal to distal end.
  • the lower skirt of fluid transfer device 100 may be configured to snap fit over the top flange of a standard medical vial.
  • fluid transfer device 100 following removal of protective cover 101, fluid transfer device 100 includes a lumen having an engagement structure 103.
  • the lumen is configured as a female bore to receive a valve actuating device 300 (shown in Fig. 5) inserted thereinto.
  • valve actuating device 300 shown in Fig. 5
  • this configuration could be modified by, for example, configuring fluid transfer device 100 as a male boss which fits into a female bore of a valve actuating device 300.
  • a "key" engagement structure 301 on the valve actuating device 300 is designed to fit into engagement structure 103 by insertion and rotation about the central axis of the lumen, thereby locking the valve actuating device into the lumen and preventing its removal until the lock is disengaged by counter-rotation about the central axis.
  • This lock-and-key structure of the engagement structure 103 with its counterpart engagement structure 301 on the valve actuating device provides at least two benefits. First, it prevents accidental attachment of a non-corresponding fitting (e.g., a standard luer fitting would not engage the engagement structure 103. Second, it provides an anchor for the driving force necessary to move the pressure member of fluid transfer device 100 is movable relative to the first outer shell from a first position to a second position, thereby opening the pressure-actuated opening and permitting fluid flow.
  • FIG. 3 provides a cross-sectional view of fluid transfer device 100 in isolation from the medicinal vessel 200.
  • the flow path 103 through the device is provided through spike member 108 until it meets a seal in the form of a resiliently deformable body 104.
  • a pre-cut slit 105 provides a pressure actuated opening; application of pressure on the central portion of the resilient body 104 causes deformation, thereby opening slit 105. Upon release of this pressure, the resilient nature of resilient body 104 causes the slit to re-seal, thereby blocking fluid flow.
  • the resiliently deformable body 104 may be made from rubber materials such as natural rubbers, silicone rubbers chlorobutyl rubbers, and the like; elsatomeroc fluoropolymers such as Kel-F®, Viton®, Kalrez®, and the like, and may have a PTFE layer facing the flow path 103 to form a chemically resistant barrier between the sample and the main seal material.
  • Pressure is applied from above the resilient body 104 by movement of actuating plunger 106 downward from the position shown in Fig. 3 to a second position which drives into resilient body 104 and activates pressure actuated opening 105.
  • This movement is affected by valve actuating device 300 as described hereinafter.
  • This actuation of pressure actuated opening 105 provides the first of a redundant set of seals which prevents undesired access to the flow of materials through the flow system. In this example, a downward movement of approximately 1.8 mm is sufficient to activate the flow system at pressure actuated opening 105.
  • the fluid transfer device 100 may be enclosed for shipping and storage in an outer enclosure 109 with a bottom closure 107 that may be peeled open to allow the end user access to the fluid transfer device 100 for use.
  • This outer enclosure 109 may be sealed during manufacturing and the entire package subjected to sterilization to ensure a sterile final product.
  • Fig. 4 provides a cross-sectional view of fluid transfer device 100 in position on medicinal vessel 200.
  • spike 108 has punctured the septum 201 of medicinal vessel 200 to allow the flow path 103 access to the interior of the vial, pressure actuated opening 105 is in its closed position, and top seal 101 has yet to be removed for use by the end user.
  • top seal 101 Upon removal of top seal 101, the lumen of fluid transfer device 100 is ready to accept valve actuating device 300.
  • "key" engagement structure 301 on the valve actuating device 300 is designed to fit into "lock” engagement structure 103 by insertion and rotation about the central axis of the lumen, thereby locking the valve actuating device into the lumen.
  • FIG. 6 A cross-sectional view of the mated devices is depicted in Fig. 6.
  • the design of valve actuating device 300 is similar to that described in US2012/0157914.
  • the outer shell 306 generally includes a proximal end, a distal end, and a passage 305 extending therebetween.
  • the inner housing 307 is slidably disposed within the outer shell 306.
  • the distal end of the inner housing 306 may include a connector including a set of connector threads 302 surrounding a boss, e.g., defining a first helical axis, for connecting the device to a fluid line.
  • the connector threads and boss are depicted as a male luer connector.
  • the connector may be replaced with alternative connector devices for connecting the system in a fluid line, or permanently connecting the valve to an outlet end of a needleless syringe for example.
  • a sealing pin 303 having a tapered end portion is disposed within a tapered or reduced diameter outlet opening of the boss. Sealing pin 303 seats on seal 304 in the closed position to provide the second of a redundant set of seals which prevents flow of materials through the system.
  • the sealing pin 303 may be formed from flexible material, e.g., silicone or other elastomeric material, for sealingly engaging seal 304 in the first position.
  • the inner housing 307 moves away from the sealing pin to open a passageway around the pin and through the open end of the boss.
  • cam features may be provided on the inner housing 307 and the outer shell 306 for limiting movement of the inner housing helically within the outer shell between the first or closed position and the second or open position.
  • a set of camming threads on the inner housing 307 define a second helical axis opposite a first helical axis on the outer shell 306.
  • this movement of the inner housing 307 also provides the force necessary to move actuating plunger 106 downward to a second position which drives into actuating plunger 106 resilient body 104 and activates pressure actuated opening 105.
  • rotation of the inner housing 307 relative to the outer shell 306 opens both redundant seals within the system, permitting flow from the reagent vial, through fluid transfer device 100, and ultimately to the outlet at the distal end of valve actuating device 300.
  • the inner housing may include one or more status indicators, e.g., that provide a visual indication when the fluid path is open.
  • a status indicator e.g., that provide a visual indication when the fluid path is open.
  • thermoplastics include PMMA, cyclic olefin copolymer, ethylene vinyl acetate, polyacrylate, polyaryletherketone, polybutadiene, polycarbonate, polyester, copolyesters,
  • polyetherimide polysulfone, nylon, polyethylene, and polystyrene.
  • Common thermosets include polyesters, polyurethanes, duroplast, epoxy resins, and polyimides. This list is not meant to be limiting.
  • Functional filler materials such as talc and carbon fibers can be included for purposes of improving stiffness, working temperatures, and part shrinkage.
  • Those portions of fluid transfer device 100 and valve actuating device 300 which contact fluid intended for patient administration are preferably biocompatible, or coated with a biocompatible material.
  • ISO-10993 The FDA has adopted the ISO-10993 standard as its criteria for guiding the selection of biocompatibility testing for a given type of device, and ISO- 10993 may therefore be used as a guide in the selection of materials for use in manufacturing various components of the devices described herein.
  • one or more components of fluid transfer device 100 and valve actuating device 300 may include one or more coatings or other materials, e.g., for reducing infection.
  • at least one of the inner housing and the shaft may include anti-adhesive material, e.g., a coating on surfaces of the inner housing and shaft exposed along the fluid path, such as a hydrophilic coating and a coating of anti- fibronectin antibodies.
  • At least one of the inner housing and shaft may include an antimicrobial agent, e.g., a coating on surfaces of the inner housing and shaft exposed along the fluid path, such as a coating including a silver ion, one or more therapeutic antibiotics, minocylcine, rifampin, and tetracycline, or one or more surfaces may be impregnated with exidine or silver sulfadiazine, ultra low fouling zwitterionic -based material, and the like.
  • an antimicrobial agent e.g., a coating on surfaces of the inner housing and shaft exposed along the fluid path, such as a coating including a silver ion, one or more therapeutic antibiotics, minocylcine, rifampin, and tetracycline, or one or more surfaces may be impregnated with exidine or silver sulfadiazine, ultra low fouling zwitterionic -based material, and the like.
  • fluid transfer device 100 is depicted in the above description as adapted to fit on a vial, the skilled artisan will readily envision other, alternative, embodiments.
  • Fig. 7 depicts a fluid transfer device 400 adapted to connect to a standard IV bag.
  • a spike member 401 enclosing a lumen 402 is depicted as a standard bag spike.
  • Lumen 402 is fluidly connected to fluid flow path 403, which meets a seal in the form of a resiliently deformable body 404.
  • a pre-cut slit 405 provides a pressure actuated opening; application of pressure on the central portion of the resilient body 404 causes deformation, thereby opening slit 105. Upon release of this pressure, the resilient nature of resilient body 404 causes the slit to re-seal, thereby blocking fluid flow.
  • valve actuating device 300 Pressure is applied from above the resilient body 404 by movement of actuating plunger 406 downward from the position shown in Fig. 6 to a second position which drives into resilient body 404 and activates pressure actuated opening 405. This movement is affected by valve actuating device 300 as described above.
  • "key" engagement structure 301 on the valve actuating device 300 is designed to fit into "lock” engagement structure 408 by insertion and rotation about the central axis of the lumen, thereby locking the valve actuating device into the lumen.
  • a replaceable cap 407 is provided as a protective cover.
  • the handling devices for chemotherapeutic agents and other highly toxic drugs of the present invention preferably contain a filter or closed system to prevent aerosolization of the vial contents due to pressure changes within the vial during reconstitution and delivery.
  • Figs. 8-12 depicts a closed system comprising a flexible enclosure 500 which provides a reservoir of air which is sealed to fluid transfer device 100 such that any aerosol that exits the vial 200 is entrapped within the enclosure.
  • the flexible reservoir comprises a sealing ring 502 and a flexible pouch 501.
  • the surface of sealing ring 502 which contacts base member 102 comprises an adhesive surface layer comprising a backing sheet having a low-adhesion surface permitting it to be peeled away from the adhesive layer and discarded.
  • the closed system is assembled by inserting the vial into pouch 501, exposing the adhesive layer and inserting pouch 501 into base member 102 as shown in Fig.
  • a backing sheet having a low-adhesion surface is peeled away from the upper surface of sealing ring 502, exposing a second adhesive layer.
  • Engagement structure 103 is then mated with this adhesive layer as depicted in Fig. 11.
  • a cap 110 is used to prevent the adhesive layers from releasing.
  • a syringe 600 mated to valve actuating device 300 may be used to withdraw contents from the vial as described above.
  • fluid transfer device 100 comprises a vent arm 111 which, when fluid transfer device 100 is mated to vial 200, provides an opening by which changes in pressure may be equalized with the atmosphere. In this alternative configuration any aerosol that exits the vial 200 is entrapped. Vent arm 111 terminates in a connector such as a Luer taper fitting which permits the attachment of a physical capture device (e.g., syringe) 700 or a filter device 800 that prevent aerosolization of vial contents.
  • a physical capture device e.g., syringe
  • a change in pressure caused by depression of syringe 600 during filling the vial 200 for reconstitution of contents will result in an equal displacement of air into syringe 700, thereby moving the plunger of syringe 700 outward.
  • a subsequent extraction of material from the vial into syringe 600 will move the plunger of syringe 700 inward.
  • the filter is selected such that air passes but not fluids. Suitable venting devices use a 0.22 micron hydrophobic filter for entrapment of aerosols.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne des dispositifs de transfert de fluide, ainsi que leurs systèmes et procédés d'utilisation pour distribuer des fluides médicaux dans une seringue, une canule telle qu'une ligne intraveineuse (IV), le corps d'un patient en aval du dispositif de transfert de fluide, etc.
EP14853288.0A 2013-10-18 2014-10-17 Dispositifs de transfert de fluide et leurs systèmes et procédés d'utilisation pour distribuer des fluides médicaux Active EP3057635B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361893066P 2013-10-18 2013-10-18
US201361894027P 2013-10-22 2013-10-22
PCT/US2014/061225 WO2015058136A1 (fr) 2013-10-18 2014-10-17 Dispositifs de transfert de fluide et leurs systèmes et procédés d'utilisation pour distribuer des fluides médicaux

Publications (3)

Publication Number Publication Date
EP3057635A1 true EP3057635A1 (fr) 2016-08-24
EP3057635A4 EP3057635A4 (fr) 2017-07-26
EP3057635B1 EP3057635B1 (fr) 2019-12-18

Family

ID=52828765

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14853288.0A Active EP3057635B1 (fr) 2013-10-18 2014-10-17 Dispositifs de transfert de fluide et leurs systèmes et procédés d'utilisation pour distribuer des fluides médicaux

Country Status (2)

Country Link
EP (1) EP3057635B1 (fr)
WO (1) WO2015058136A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006264300B2 (en) 2005-07-06 2012-03-08 Vascular Pathways Inc. Intravenous catheter insertion device and method of use
JP5139518B2 (ja) 2007-05-07 2013-02-06 バスキュラー・パスウェイズ・インコーポレイテッド 静脈カテーテル挿入装置
US8932258B2 (en) 2010-05-14 2015-01-13 C. R. Bard, Inc. Catheter placement device and method
US9872971B2 (en) 2010-05-14 2018-01-23 C. R. Bard, Inc. Guidewire extension system for a catheter placement device
US11925779B2 (en) 2010-05-14 2024-03-12 C. R. Bard, Inc. Catheter insertion device including top-mounted advancement components
US10384039B2 (en) 2010-05-14 2019-08-20 C. R. Bard, Inc. Catheter insertion device including top-mounted advancement components
US9950139B2 (en) 2010-05-14 2018-04-24 C. R. Bard, Inc. Catheter placement device including guidewire and catheter control elements
US8690833B2 (en) 2011-01-31 2014-04-08 Vascular Pathways, Inc. Intravenous catheter and insertion device with reduced blood spatter
CN103379937B (zh) 2011-02-25 2016-09-07 C·R·巴德股份有限公司 包括可缩回的针的医疗部件插入设备
USD903101S1 (en) 2011-05-13 2020-11-24 C. R. Bard, Inc. Catheter
US10232146B2 (en) 2014-09-05 2019-03-19 C. R. Bard, Inc. Catheter insertion device including retractable needle
USD903100S1 (en) 2015-05-01 2020-11-24 C. R. Bard, Inc. Catheter placement device
US11040176B2 (en) 2015-05-15 2021-06-22 C. R. Bard, Inc. Catheter placement device including an extensible needle safety component
US10493262B2 (en) 2016-09-12 2019-12-03 C. R. Bard, Inc. Blood control for a catheter insertion device
EP3585471A4 (fr) 2017-03-01 2021-03-10 C.R. Bard, Inc. Dispositif d'insertion de cathéter
EP4364779A3 (fr) 2018-03-07 2024-07-31 Bard Access Systems, Inc. Systèmes d'avancement de fil-guide et de retour de sang pour un système d'insertion de dispositif médical
USD921884S1 (en) 2018-07-27 2021-06-08 Bard Access Systems, Inc. Catheter insertion device
BR112022003173A2 (pt) 2019-08-19 2022-05-17 Becton Dickinson Co Dispositivo de colocação de cateter de linha média

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US271421A (en) 1883-01-30 Mechanism for converting motion
US3757981A (en) 1969-11-24 1973-09-11 Harris R Valves and valve needle syringes
US3618637A (en) 1970-02-04 1971-11-09 Deseret Pharma Rotary mixing valve
US3826261A (en) 1971-12-27 1974-07-30 Upjohn Co Vial and syringe assembly
US3977555A (en) 1974-05-07 1976-08-31 Pharmaco, Inc. Protective safety cap for medicament vial
US3957052A (en) 1974-09-13 1976-05-18 Medical Development Corporation Pumping-syringe
US3993063A (en) 1975-06-16 1976-11-23 Union Carbide Corporation Protective shielding assembly for use in loading a hypodermic syringe with radioactive material
US4051852A (en) 1975-06-26 1977-10-04 The Kendall Company Aspirating device
CA1215945A (fr) 1983-03-20 1986-12-30 Bengt Gustavsson Systeme de transfert de fluides
US4604093A (en) 1984-06-12 1986-08-05 I-Flow Corporation Apparatus and method for administering multiple fluid infusions
US4607671A (en) 1984-08-21 1986-08-26 Baxter Travenol Laboratories, Inc. Reconstitution device
US4759756A (en) 1984-09-14 1988-07-26 Baxter Travenol Laboratories, Inc. Reconstitution device
US4721133A (en) 1985-09-26 1988-01-26 Alcon Laboratories, Inc. Multiple use valving device
SE461765B (sv) 1986-07-10 1990-03-26 Haessle Ab Anordning foer frisaettning av substans
IT1201801B (it) 1986-08-04 1989-02-02 Pietro Cosmai Caricatore miscelatore per iniettori transcutanei
US4758235A (en) 1987-05-26 1988-07-19 Tu Ho C Cardiopulmonary resuscitation medication assembly
US4967797A (en) 1989-08-16 1990-11-06 Manska Wayne E Tap valve
US4997430A (en) 1989-09-06 1991-03-05 Npbi Nederlands Produktielaboratorium Voor Bloedtransfusieapparatuur En Infusievloeistoffen B.V. Method of and apparatus for administering medicament to a patient
US5288290A (en) 1991-09-25 1994-02-22 Alcon Surgical, Inc. Multi-ported valve assembly
US5279576A (en) 1992-05-26 1994-01-18 George Loo Medication vial adapter
US5334163A (en) 1992-09-16 1994-08-02 Sinnett Kevin B Apparatus for preparing and administering a dose of a fluid mixture for injection into body tissue
US5269768A (en) 1993-02-08 1993-12-14 Smiths Industries Medical Systems, Inc. Valved suction catheter
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
IL114960A0 (en) * 1995-03-20 1995-12-08 Medimop Medical Projects Ltd Flow control device
US6875205B2 (en) 2002-02-08 2005-04-05 Alaris Medical Systems, Inc. Vial adapter having a needle-free valve for use with vial closures of different sizes
US7645274B2 (en) * 2004-12-10 2010-01-12 Cardinal Health 303, Inc. Self-sealing male luer connector with multiple seats
US7347458B2 (en) * 2005-01-14 2008-03-25 C. R. Bard, Inc. Locking luer fitting
US7998134B2 (en) * 2007-05-16 2011-08-16 Icu Medical, Inc. Medical connector
WO2007015233A1 (fr) * 2005-08-01 2007-02-08 Medimop Medical Projects Ltd Système de délivrance de médicament liquide
JP5329546B2 (ja) * 2007-09-17 2013-10-30 カルメル ファルマ アクチボラゲット バッグコネクタ
US8603047B2 (en) 2010-12-15 2013-12-10 Infusion Innovations Devices, assemblies and methods for controlling fluid flow

Also Published As

Publication number Publication date
EP3057635B1 (fr) 2019-12-18
WO2015058136A1 (fr) 2015-04-23
EP3057635A4 (fr) 2017-07-26

Similar Documents

Publication Publication Date Title
EP3057635B1 (fr) Dispositifs de transfert de fluide et leurs systèmes et procédés d'utilisation pour distribuer des fluides médicaux
JP7004757B2 (ja) ロッキング部材を含む、流体の密閉された移送のためのシステム
EP1976588B1 (fr) Capsule d'amorçage de protection pour soupape luer male auto-etanche
US10850087B2 (en) Fluid transfer device and packaging therefor
US20240108548A1 (en) Pre-filled diluent syringe vial adapter
CA2346468C (fr) Systeme a point de penetration sans aiguille, nettoyable, a faible reflux
EP2756863B1 (fr) Dispositif de connexion à verrouillage pour conduit de fluide médical
EP3781237B1 (fr) Adaptateur de seringue avec ensemble aspiration
CA2650966A1 (fr) Dispositif d'acces ventile pour infusions
EP3562753B1 (fr) Fermeture de récipient actionnée par un dispositif de connexion
AU2011217306A1 (en) Closure cap for a receptacle for receiving medical liquids, and receptacle
US11826542B2 (en) Medical infusion device and methods of use
EP3062868A1 (fr) Dispositifs, ensembles et procédés pour réguler un écoulement de fluide
US20090204080A1 (en) Two-way valve connector
KR20190102176A (ko) 회전에 의해 조작되는 컨테이너 마개
US20240269042A1 (en) Closed sterile medication mixing and/or administration system with disinfection options
US20240024589A1 (en) Sterile drug chamber valve
WO2024173302A1 (fr) Système de mélange et/ou d'administration de médicament stérile et fermé avec options de désinfection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170627

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 5/32 20060101AFI20170621BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180720

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190703

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014058729

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1213887

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200115

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200319

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200418

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014058729

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1213887

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191218

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

26N No opposition filed

Effective date: 20200921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201017

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220901

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220908

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20220831

Year of fee payment: 9

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602014058729

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20231017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231017

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240501